Wuhan Hvsen Biotechnology Co Ltd

Chart & Performance

D1W1MN

P/E

18.02

P/S

2.71

EPS

1.25

Div Yield, %

0.91%

Shrs. gr., 5y

4.07%

Rev. gr., 5y

11.03%

Revenues

1.68b

+40.07%

Net income

253m

CFO

238m

+447.76%

Dividend

Aug 26, 20250.1 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Hvsen Biotechnology Co., Ltd. is a company based in Wuhan, China, that focuses on the global research, development, and manufacturing of macrolide active pharmaceutical ingredients (APIs) and finished drug products. The company's diverse product portfolio features tylvalosin, offered in both raw material form and various preparations, along with florfenicol preparations and a broader selection of other macrolide-based offerings. Additionally, Hvsen produces a range of veterinary pharmaceuticals, available as both raw ingredients and finished drugs, alongside traditional Chinese medicine extracts.

URL

http://www.whhsyy.com/

IPO date

Aug 24, 2020

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2023‑00	2022‑12	2022‑00	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT